Wells Fargo initiated coverage of ResMed (RMD) with an Equal Weight rating and $280 price target The firm’s survey of 50 sleep specialists in the U.S. suggests that U.S. PAP market growth may be trending below Street expectations, in part driven by GLP-1 uptake. By contrast, Street estimates are for ResMed’s U.S. devices growth of +6.2% year-over-year and U.S. masks growth of +11.6% year-over-year in FY26. While Wells’ survey does not capture PAP prescriptions by PCPs, the firm believes that it implies limited upside to expectations.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Resmed’s Strategic Positioning and Growth Prospects: A Buy Recommendation by Laura Sutcliffe
- Resmed’s Strategic Growth and Competitive Edge Support Buy Rating with $300 Price Target
- ResMed U.S. shares initiated with a Buy at Citi
- ResMed participates in a conference call with KeyBanc
- ResMed launches Sleep Institute